189 related articles for article (PubMed ID: 2224866)
21. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody.
Wang Z; Zhang T; Hu H; Zhang H; Yang Z; Cui L; He W
Cancer Lett; 2008 Dec; 272(2):242-52. PubMed ID: 18782650
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: comparison between in vitro and in vivo disposition.
Mano Y; Suzuki H; Terasaki T; Iwahashi T; Ono K; Naito M; Tsuruo T; Sugiyama Y
J Pharmacol Exp Ther; 1997 Oct; 283(1):391-401. PubMed ID: 9336348
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
24. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
26. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
29. Effect of heterogeneous vasculature on interstitial transport within a solid tumor.
Zhao J; Salmon H; Sarntinoranont M
Microvasc Res; 2007 May; 73(3):224-36. PubMed ID: 17307203
[TBL] [Abstract][Full Text] [Related]
30. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors.
Bjorn MJ; Groetsema G
Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979
[TBL] [Abstract][Full Text] [Related]
31. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
32. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
33. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
36. Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.
Byers VS; Pawluczyk IZ; Hooi DS; Price MR; Carroll S; Embleton MJ; Garnett MC; Berry N; Robins RA; Baldwin RW
Cancer Res; 1991 Apr; 51(8):1990-5. PubMed ID: 2009518
[TBL] [Abstract][Full Text] [Related]
37. Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.
Blasberg RG; Nakagawa H; Bourdon MA; Groothuis DR; Patlak CS; Bigner DD
Cancer Res; 1987 Aug; 47(16):4432-43. PubMed ID: 3607773
[TBL] [Abstract][Full Text] [Related]
38. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
39. Brain iron homeostasis.
Moos T
Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
[TBL] [Abstract][Full Text] [Related]
40. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier".
van Osdol W; Fujimori K; Weinstein JN
Cancer Res; 1991 Sep; 51(18):4776-84. PubMed ID: 1893370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
